BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 35833288)

  • 21. Diagnostic Accuracy of
    Sprute K; Kramer V; Koerber SA; Meneses M; Fernandez R; Soza-Ried C; Eiber M; Weber WA; Rauscher I; Rahbar K; Schaefers M; Watabe T; Uemura M; Naka S; Nonomura N; Hatazawa J; Schwab C; Schütz V; Hohenfellner M; Holland-Letz T; Debus J; Kratochwil C; Amaral H; Choyke PL; Haberkorn U; Sandoval C; Giesel FL
    J Nucl Med; 2021 Feb; 62(2):208-213. PubMed ID: 32817141
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Detection level and pattern of positive lesions using PSMA PET/CT for staging prior to radiation therapy.
    Schmidt-Hegemann NS; Fendler WP; Buchner A; Stief C; Rogowski P; Niyazi M; Eze C; Li M; Bartenstein P; Belka C; Ganswindt U
    Radiat Oncol; 2017 Nov; 12(1):176. PubMed ID: 29126446
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk of metastatic disease on
    Yaxley JW; Raveenthiran S; Nouhaud FX; Samaratunga H; Yaxley WJ; Coughlin G; Yaxley AJ; Gianduzzo T; Kua B; McEwan L; Wong D
    BJU Int; 2019 Sep; 124(3):401-407. PubMed ID: 31141284
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gallium 68 PSMA-11 PET/MR Imaging in Patients with Intermediate- or High-Risk Prostate Cancer.
    Park SY; Zacharias C; Harrison C; Fan RE; Kunder C; Hatami N; Giesel F; Ghanouni P; Daniel B; Loening AM; Sonn GA; Iagaru A
    Radiology; 2018 Aug; 288(2):495-505. PubMed ID: 29786490
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Prospective Comparison of
    Anttinen M; Ettala O; Malaspina S; Jambor I; Sandell M; Kajander S; Rinta-Kiikka I; Schildt J; Saukko E; Rautio P; Timonen KL; Matikainen T; Noponen T; Saunavaara J; Löyttyniemi E; Taimen P; Kemppainen J; Dean PB; Blanco Sequeiros R; Aronen HJ; Seppänen M; Boström PJ
    Eur Urol Oncol; 2021 Aug; 4(4):635-644. PubMed ID: 32675047
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of
    Schwenck J; Rempp H; Reischl G; Kruck S; Stenzl A; Nikolaou K; Pfannenberg C; la Fougère C
    Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):92-101. PubMed ID: 27557844
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multiphasic
    Beheshti M; Manafi-Farid R; Geinitz H; Vali R; Loidl W; Mottaghy FM; Langsteger W
    J Nucl Med; 2020 Oct; 61(10):1484-1490. PubMed ID: 32060214
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High negative predictive value of 68Ga PSMA PET-CT for local lymph node metastases in high risk primary prostate cancer with histopathological correlation.
    Rahman LA; Rutagengwa D; Lin P; Lin M; Yap J; Lai K; Mancuso P; Rathore P; Haghighi K; Gassner P; Wong LH; Lalak N
    Cancer Imaging; 2019 Dec; 19(1):86. PubMed ID: 31829288
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Multicenter Prospective Clinical Trial of
    McCarthy M; Francis R; Tang C; Watts J; Campbell A
    Int J Radiat Oncol Biol Phys; 2019 Jul; 104(4):801-808. PubMed ID: 30890448
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prospective intra-individual blinded comparison of [
    Pattison DA; Debowski M; Gulhane B; Arnfield EG; Pelecanos AM; Garcia PL; Latter MJ; Lin CY; Roberts MJ; Ramsay SC; Thomas PA
    Eur J Nucl Med Mol Imaging; 2022 Jan; 49(2):763-776. PubMed ID: 34383089
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Value of 68Ga-PSMA HBED-CC PET for the Assessment of Lymph Node Metastases in Prostate Cancer Patients with Biochemical Recurrence: Comparison with Histopathology After Salvage Lymphadenectomy.
    Rauscher I; Maurer T; Beer AJ; Graner FP; Haller B; Weirich G; Doherty A; Gschwend JE; Schwaiger M; Eiber M
    J Nucl Med; 2016 Nov; 57(11):1713-1719. PubMed ID: 27261524
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of hybrid
    Janssen JC; Meißner S; Woythal N; Prasad V; Brenner W; Diederichs G; Hamm B; Makowski MR
    Eur Radiol; 2018 Feb; 28(2):610-619. PubMed ID: 28779400
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison between pelvic PSMA-PET/MR and whole-body PSMA-PET/CT for the initial evaluation of prostate cancer: a proof of concept study.
    Domachevsky L; Bernstine H; Goldberg N; Nidam M; Catalano OA; Groshar D
    Eur Radiol; 2020 Jan; 30(1):328-336. PubMed ID: 31332559
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Distribution of prostate cancer recurrences on gallium-68 prostate-specific membrane antigen (
    Huits TH; Luiting HB; van der Poel HG; Nandurkar R; Donswijk M; Schaake E; Vogel W; Roobol MJ; Wit E; Stricker P; Emmett L; van Leeuwen PJ
    BJU Int; 2020 Jun; 125(6):876-883. PubMed ID: 32181951
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prostate-specific membrane antigen-guided salvage lymph node dissection in recurrent prostate cancer: a novel technology to detect lymph node metastases.
    Maurer T; Gschwend JE; Eiber M
    Curr Opin Urol; 2018 Mar; 28(2):191-196. PubMed ID: 29028767
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Accuracy of 68Ga-PSMA PET-CT and PET-MRI in lymph node staging for localized prostate cancer.
    Barbosa ÁRG; Amaral BS; Lourenço DB; Bianco B; Gushiken FA; Apezzato M; Silva JF; Cunha MLD; Filippi RZ; Baroni RH; Lemos GC; Carneiro A
    Einstein (Sao Paulo); 2022; 20():eAO6599. PubMed ID: 35584444
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prospective Comparison of PET Imaging with PSMA-Targeted
    Rowe SP; Li X; Trock BJ; Werner RA; Frey S; DiGianvittorio M; Bleiler JK; Reyes DK; Abdallah R; Pienta KJ; Gorin MA; Pomper MG
    J Nucl Med; 2020 Feb; 61(2):183-188. PubMed ID: 31451492
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PSMA-Based [(18)F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer.
    Rowe SP; Macura KJ; Mena E; Blackford AL; Nadal R; Antonarakis ES; Eisenberger M; Carducci M; Fan H; Dannals RF; Chen Y; Mease RC; Szabo Z; Pomper MG; Cho SY
    Mol Imaging Biol; 2016 Jun; 18(3):411-9. PubMed ID: 27080322
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 68Ga-PSMA PET/CT in prostate cancer patients - patterns of disease, benign findings and pitfalls.
    Keidar Z; Gill R; Goshen E; Israel O; Davidson T; Morgulis M; Pirmisashvili N; Ben-Haim S
    Cancer Imaging; 2018 Nov; 18(1):39. PubMed ID: 30382889
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of gallium-68 prostate-specific membrane antigen positron-emission tomography for detecting lymph node metastases in primary and recurrent prostate cancer and location of recurrence after radical prostatectomy: an overview of the current literature.
    Luiting HB; van Leeuwen PJ; Busstra MB; Brabander T; van der Poel HG; Donswijk ML; Vis AN; Emmett L; Stricker PD; Roobol MJ
    BJU Int; 2020 Feb; 125(2):206-214. PubMed ID: 31680398
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.